2:18 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Preclinical News

Praxis debuts with abuse-deterrent stimulant

Praxis Bioresearch LLC (Menlo Park, Calif.) unveiled its lead candidate PRX-P4-003, an abuse-deterrent prodrug of the stimulant fencamfamine, and presented preclinical data for the compound on Thursday at the American College of Neuropsychopharmacology meeting in Palm Springs, Calif. The company, which has operated in stealth since 2014, is developing therapeutics to treat chronic neuropsychiatric and neurodegenerative disorders.

PRX-P4-003 is...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >